Around 200 generic drugs go on and off drug shortage lists in the United States, with dangerous outcomes for patients and costly consequences for hospitals. In a bid to get these shortages under control, seven hospital groups and three health-care foundations recently launched the non-profit generic drug company Civica Rx. In September they named Martin VanTrieste, former chief quality officer for Amgen, as CEO of this venture. Civica Rx plans to start distributing the first of its products as soon as 2019. VanTrieste told Asher Mullard about how this non-profit stands to bring stability to the notoriously turbulent generic market, and how it will ensure that it doesn't exacerbate the problem it is trying to solve.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Martin VanTrieste. Nat Rev Drug Discov 17, 780–781 (2018). https://doi.org/10.1038/nrd.2018.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.193
